Semiramis Ayral‐Kaloustian

Biochemical, Cellular, and <i>In vivo</i> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral‐Barza, Celine Shi et al. · Cancer Research · 2009 · 330 citations

Medicine, Oncology, Pharmacology +13

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound <b>26</b> (PKI-587), a Highly Efficacious Dual Inhibitor

Aranapakam M. Venkatesan, Christoph M. Dehnhardt, Efren Delos Santos et al. · Journal of Medicinal Chemistry · 2010 · 212 citations · Full text

Medicine, Oncology, Pharmacology +14

Synthesis and SAR of [1,2,4]Triazolo[1,5-<i>a</i>]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition

Nan Zhang, Semiramis Ayral‐Kaloustian, Thai Nguyen et al. · Journal of Medicinal Chemistry · 2006 · 211 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Ker Yu, Celine Shi, Lourdes Toral‐Barza et al. · Cancer Research · 2010 · 208 citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

Robert Mallon, Larry Feldberg, Judy Lucas et al. · Clinical Cancer Research · 2011 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17